Search clinical trials for: dihydroergotamine

Total 18 results

Satsuma Pharmaceuticals, Inc.

Completed

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine (SUMMIT)

Migraine | Migraine Without Aura | Migraine With Aura

United States
Satsuma Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine (ASCEND)

Migraine | Migraine Without Aura | Migraine With Aura

United States
Satsuma Pharmaceuticals, Inc.

Completed

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine (EMERGE)

Migraine | Migraine Without Aura | Migraine With Aura

United States
Pulmatrix Inc.

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults

Healthy

Australia
Satsuma Pharmaceuticals, Inc.

Completed

A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Migraine | Migraine Without Aura | Migraine With Aura

United States
Thomas Jefferson University

Completed

A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine

Migraine

United States
Kimberly S Jones

Terminated

Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

Migraine in Children

United States
Impel Pharmaceuticals

Completed

Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)

Migraine Headache

United States
Satsuma Pharmaceuticals, Inc.

Completed

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Migraine | Migraine Without Aura | Migraine With Aura

United States
Ache Laboratorios Farmaceuticos S.A.

Suspended

Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks

Migraine

Brazil
Ache Laboratorios Farmaceuticos S.A.

Withdrawn

Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks

Migraine Headache

Brazil
Impel Pharmaceuticals

Completed

Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

Migraine Headache

Australia
Thomas Jefferson University
Bausch Health Americas, Inc.

Completed

A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity

Migraine

United States
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Completed

Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers

Healthy Subjects

United Kingdom
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Completed

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

Healthy

United States
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Completed

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

Healthy

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects

Renal Insufficiency

Hungary
Shiraz University of Medical Sciences

Unknown

Effect of Dexamethasone on Migraine Headache

Migraine Headache

Iran, Islamic Republic of

3

Subscribe